Skip to main content
Explore URMC

menu

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients

Research Question:
Does the drug Pevonedistat help the survival of patients with relapsed/refractory myelodysplastic syndrome or myelodysplastic/ myeloproliferative overlap syndromes who are not eligible for hematopoietic stem cell transplant?

Basic Study Information

Purpose:
The purpose of this study is to compare survival of patients treated with a combination of pevonedistat and azacitidine after failure of DNA methyltransferase inhibitors to historical survival for patients with relapsed/refractory myelodysplastic syndrome or myelodysplastic/ myeloproliferative overlap syndromes who are ineligible for hematopoietic stem cell transplant.

Study Reference #: UMDS18055

Lead Researcher (Principal Investigator)

Lead Researcher: Jason Mendler

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search